Merck Bets Moderna's Cancer Vaccines Can Prime Patients For Immunotherapy
Executive Summary
The companies will work together to develop personalized cancer vaccines against several tumor types, including an effort to pair a personalized vaccine with Keytruda.
You may also be interested in...
Moderna Chalks Up Industry Milestone With mRNA Cancer Vaccine Efficacy Success
Phase IIb KEYNOTE-942 study shows mRNA-4157/V940 paired with Keytruda reduces risk of recurrence and death in post-surgical melanoma patients compared with Keytruda alone.
Merck & Co. Pounces On Moderna mRNA-Based Cancer Vaccine Option
The company will pay Moderna $250m upfront to develop and commercialize a personalized cancer vaccine for melanoma in combination with Keytruda.
Amgen's KRAS Inhibitor AMG 510 Leans Toward Tumor-Dependent, Not Agnostic, Approach
SVP Elliott Levy said the company hasn't ruled out a tumor-agnostic approach for AMG 510, but Phase I data for the first-in-class drug show a bigger effect in lung cancer – a 50% response rate, so far – than in colorectal cancer patients with a KRAS G12C mutation.